Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Generate Investment Management Ltd

Generate Investment Management Ltd lowered its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 27.2% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 7,841 shares of the biopharmaceutical company’s stock after selling 2,923 shares during the quarter. Generate Investment Management Ltd’s holdings in Regeneron Pharmaceuticals were worth $5,585,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of REGN. Mizuho Securities USA LLC boosted its position in shares of Regeneron Pharmaceuticals by 625.5% during the 3rd quarter. Mizuho Securities USA LLC now owns 59,341 shares of the biopharmaceutical company’s stock worth $62,382,000 after purchasing an additional 51,162 shares during the period. Principal Financial Group Inc. lifted its stake in Regeneron Pharmaceuticals by 1.7% during the third quarter. Principal Financial Group Inc. now owns 173,092 shares of the biopharmaceutical company’s stock worth $181,961,000 after purchasing an additional 2,828 shares in the last quarter. Simplify Asset Management Inc. grew its stake in shares of Regeneron Pharmaceuticals by 50.8% in the third quarter. Simplify Asset Management Inc. now owns 9,591 shares of the biopharmaceutical company’s stock valued at $10,082,000 after buying an additional 3,231 shares in the last quarter. Golden State Equity Partners raised its holdings in shares of Regeneron Pharmaceuticals by 1,479.1% in the 4th quarter. Golden State Equity Partners now owns 1,358 shares of the biopharmaceutical company’s stock valued at $967,000 after buying an additional 1,272 shares during the period. Finally, Catalytic Wealth RIA LLC acquired a new position in Regeneron Pharmaceuticals during the 3rd quarter worth about $1,334,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $710.00 on Friday. The stock’s 50-day moving average is $716.62 and its two-hundred day moving average is $913.59. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. Regeneron Pharmaceuticals, Inc. has a 1 year low of $642.00 and a 1 year high of $1,211.20. The firm has a market cap of $78.02 billion, a price-to-earnings ratio of 17.57, a PEG ratio of 1.60 and a beta of 0.08.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.88% and a net margin of 33.61%. The firm had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. During the same quarter last year, the business posted $11.86 EPS. The firm’s quarterly revenue was up 10.3% compared to the same quarter last year. Analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.75 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be given a $0.88 dividend. The ex-dividend date of this dividend is Thursday, February 20th. This represents a $3.52 annualized dividend and a yield of 0.50%.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. BMO Capital Markets dropped their target price on Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating for the company in a research report on Tuesday. Leerink Partnrs raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Wednesday. Bank of America reissued an “underperform” rating and issued a $565.00 price target on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 10th. UBS Group lowered Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $1,130.00 to $738.00 in a research report on Thursday, January 16th. Finally, Bernstein Bank decreased their target price on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a report on Tuesday. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $973.13.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.